• BetterLife Pharma’s (CSE:BETR) launch of its branded products is still on target, despite disruptions to the global supply chains 
  • The company will launch its white-labelled and patent-protected products in 2020’s second quarter
  • BetterLife is accelerating the launch of CBD supplements product line in the third quarter
  • The company has also announced an amicable resolution to its disputes with former executives, Patrick J Rolfes and Ross Franklin
  • BetterLife Pharma’s (BETR) share price remains unchanged, and is currently trading for 7.5 cents per share

BetterLife Pharma’s (CSE:BETR) launch of its branded products is still on target, despite COVID-related disruptions to global supply chains.

The company intends to launch its white-labelled and patent-protected products in a direct-to-consumer model in 2020’s second quarter.

The first range of products to launch under the brand available in the US will include topicals, tinctures and gummies. 

In addition, BetterLife is accelerating the launch of a CBD supplements product line in the third quarter. The line will include CBD multi-benefit supplements and immunity-boosting products. 

The company could be accelerating the launch in order to capitalise on increased demand for CBD products, caused by COVID-19. Many cannabis companies have reported significant increases in sales since fears started setting in about the pandemic. 

BetterLife’s Interim CEO, Ahmad Doroudian, commented on how the company is getting on with the job. 

“During the first quarter, BetterLife’s operations and scientific team successfully transferred its formulations to commercial manufacturing facilities in the US. Mr Joseph Mimran and his consulting firm developed the branding and packaging for our branded products.

I want to thank both teams, who worked tirelessly in a very challenging environment to ensure the successful launch of our products in the coming weeks,” he said.

BetterLife has indicated that it will continue to aggressively pursue opportunities for mergers and acquisitions in the future. 

In other news, the company has announced an amicable resolution to all of its disputes with former executives, Patrick J Rolfes and Ross Franklin. 

BetterLife Pharma’s (BETR) share price remains unchanged, and is trading for 7.5 cents per share as of 2:05pm EST.

More From The Market Online

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.
WELL Health - Hamed Shahbazi, Founder and CEO (third from right).

WELL Health streamlining business towards profitable growth

WELL Health (TSX:WELL) has made an integration update to streamline its business operations and position itself for profitable growth.

An investor’s gateway into the cancer immunotherapy market is with this Canadian biotechnology company 

The overarching cancer immunotherapy market continues growing at unprecedented rates, and BioVaxys Technology is ready to capitalize on it.

Buzz on the Bullboards: Where volatility meets opportunity

Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day.